Last Updated: 01/10/2025
Drug Resistant Malaria in Africa: Optimizing criteria and developing a rapid test for artemisinin resistance
Objectives
The goal of this project is to develop and validate an Africa-specific cutoff for artemisinin resistance that accounts for acquired malaria immunity, thereby enabling the establishment of reliable genetic markers to accurately monitor and track drug resistance across the continent.
95% of the world’s three major infectious diseases, malaria, occur in Africa. It was reported for the first time that resistance to first-line drug artemisinin has appeared in Africa. Current artemisinin resistance cutoff is based on a study in Asia. However, unlike in Asia, people in Africa have a high level of acquired malaria-immunity, so some resistant parasites are eliminated by immunity. Applying Asia cutoffs to Africa risks underestimating resistance. Therefore, a novel cutoff for Africa will be developed and used to develop reliable resistance gene markers.
Apr 2024 — Mar 2027
$30,900
Related Resources
